Subject: Pharma Leaders And Innovative Drug Delivery Solution Providers To Meet At World Drug Delivery Congress 2011

From the 5th to the 7th of September 2011, pharmaceutical, drug delivery and formulations leaders from Asia and the rest of the world will meet at World Drug Delivery Congress 2011. The event will be hosted by IMAPAC in Singapore.

It is indeed an exciting time for Asian pharmas. Today, they are no longer falling too far behind their Western counterparts in terms of innovations as the patent cliffs and high generic competition in the region has driven the need to innovate to an even higher level. Many have recognized how important it is to innovate on their formulation and delivery systems, but access to novel technologies remains a challenge. Hence, it is great to know that such a meeting is taking place in the region where industry leaders could share, network and learn."

According to Jack Aurora, Chief Scientific Officer of Hisun Pharmaceutical in China "The drug delivery industry has been growing rapidly throughout the world. The industry has recognized that it is not only a life cycle management strategy; it is also one which can bring about a positive impact on the lives of many millions of patients in terms of treatment plan and cost".

And bring about a positive impact are these leading pharmas who have transformed themselves.

Take United Laboratories, the leading pharmaceutical manufacturer in Philippines, if not in Asia, for example. Their secret to success lies in constant innovations in terms of novel formulations. US patented technologies such as TasteRite and SureDose are a sign of the pharma giant's commitment to listening to their consumers and providing a solution that serves them.

In Malaysia, Hovid has pride itself to be the country's leading pharmaceutical manufacturers by investing in their pillar of growth of innovations. They are a pioneer in several development innovations which includes patented drug delivery systems for controlled release and enhanced oral bioavailability.

And to top it all off, Biocon in India, has taken a great leap into the "holy grail" of diabetes management by taking on the development of oral insulin. The novel development has gained worldwide hype and is clearly a strategy for the pharma to stay ahead of the game.

Featuring key speakers like include Jack Aurora, CSO, of Hisun pharma in China, Ursula Redeker, Head of Technical Dev Biologics from F. Hoffman La-Roche, David Monteith, Head pharmaceutical developments, Emerging markets Merck and Kennie Dee, Vice president for R&D in Unilabs Philippines, the event is where Asian and global pharma leaders gather with solution providers to exchange ideas and debate on how to leverage on innovative drug delivery technologies to create more value in their product pipelines.

Over 80 pharmaceutical manufacturers including international players such as Roche, Novo Nordisk, Merck, Boehringer Ingelheim, as well as leading Asian industry leaders such as Hisun Pharmaceuticals, Dr Reddy's and United laboratories will be involved at the event. They will be joined by potential solution providers such as SHL Group, Bespak, Colorcon and BASF among others.

This is Asia Pacific region's first and highest level gathering that brings together key decision makers in the pharmaceutical industry in a never been done before event. Discussions are set to range from the developments of innovative drug formulation and delivery strategies, to the ability to create new revenue streams and sustainable partnerships.

World Drug Delivery Congress is also set to showcase new and innovative solution providers and will be a platform for new partnerships to be formed as many turn to the burgeoning growth the emerging markets has to offer.

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.